Alharbi, A.; Khobrani, A.; Noor, A.; Alghamdi, W.; Alotaibi, A.; Alnuhait, M.; Haseeb, A.
Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors. Int. J. Environ. Res. Public Health 2023, 20, 580.
https://doi.org/10.3390/ijerph20010580
AMA Style
Alharbi A, Khobrani A, Noor A, Alghamdi W, Alotaibi A, Alnuhait M, Haseeb A.
Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors. International Journal of Environmental Research and Public Health. 2023; 20(1):580.
https://doi.org/10.3390/ijerph20010580
Chicago/Turabian Style
Alharbi, Ahmad, Attiah Khobrani, Afnan Noor, Waad Alghamdi, Abdulmalik Alotaibi, Mohammed Alnuhait, and Abdul Haseeb.
2023. "Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors" International Journal of Environmental Research and Public Health 20, no. 1: 580.
https://doi.org/10.3390/ijerph20010580
APA Style
Alharbi, A., Khobrani, A., Noor, A., Alghamdi, W., Alotaibi, A., Alnuhait, M., & Haseeb, A.
(2023). Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors. International Journal of Environmental Research and Public Health, 20(1), 580.
https://doi.org/10.3390/ijerph20010580